Alnylam Pharmaceuticals, Inc. (ALNY)
Automate Your Wheel Strategy on ALNY
With Tiblio's Option Bot, you can configure your own wheel strategy including ALNY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ALNY
- Rev/Share 18.9855
- Book/Share 1.9324
- PB 235.9712
- Debt/Equity 5.176
- CurrentRatio 2.801
- ROIC -0.0457
- MktCap 59772030840.0
- FreeCF/Share -0.4017
- PFCF -1147.5202
- PE -185.3159
- Debt/Assets 0.2841
- DivYield 0
- ROE -2.7421
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | ALNY | Wolfe Research | Underperform | Peer Perform | -- | -- | Aug. 4, 2025 |
| Upgrade | ALNY | Oppenheimer | Perform | Outperform | -- | $490 | Aug. 4, 2025 |
| Resumed | ALNY | Raymond James | -- | Outperform | -- | $370 | July 30, 2025 |
| Initiation | ALNY | Truist | -- | Buy | -- | $385 | July 21, 2025 |
| Initiation | ALNY | Redburn Atlantic | -- | Buy | -- | $353 | March 31, 2025 |
| Upgrade | ALNY | JP Morgan | Neutral | Overweight | $280 | $328 | March 24, 2025 |
| Initiation | ALNY | Scotiabank | -- | Sector Outperform | -- | -- | Oct. 16, 2024 |
| Upgrade | ALNY | Goldman | Neutral | Buy | $198 | $370 | Aug. 16, 2024 |
News
Alnylam: Waiting For Regulatory Updates In March
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Positive
Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR franchise implies modest growth acceleration compared to 2024, driven by Amvuttra's expected approval next month. Fitusiran's approval could result in meaningful annual royalties for Alnylam from partner Sanofi, enhancing long-term profitability and cash flows.
Read More
ILMN vs. ALNY: Which Stock Is the Better Value Option?
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Illumina (ILMN) and Alnylam Pharmaceuticals (ALNY). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.
Read More
About Alnylam Pharmaceuticals, Inc. (ALNY)
- IPO Date 2004-06-01
- Website https://www.alnylam.com
- Industry Biotechnology
- CEO Yvonne L. Greenstreet
- Employees 2230